Anne E Deckert1, Richard J Reid-Smith1, Susan E Tamblyn2, Larry Morrell3, Patrick Seliske4, Frances B Jamieson5, Rebecca Irwin6, Catherine E Dewey7, Patrick Boerlin8, Scott A McEwen7. 1. Department of Population Medicine, University of Guelph; ; Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Guelph; 2. Public Health Consultant, Stratford; 3. Perth District Health Unit, Stratford; 4. Wellington-Dufferin-Guelph District Health Unit, Guelph; 5. Public Health Ontario, Toronto; 6. Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Guelph; 7. Department of Population Medicine, University of Guelph; 8. Department of Pathobiology, University of Guelph, Guelph, Ontario.
Abstract
AIM: A population-based study was conducted over a two-year period in the Perth District (PD) and Wellington-Dufferin-Guelph (WDG) health units in Ontario to document antimicrobial resistance and antimicrobial use associated with clinical cases of laboratory-confirmed campylobacteriosis. METHODS: Etest (bioMérieux SA, France) was used to determine the minimum inhibitory concentration of amoxicillin/clavulanic acid, ampicillin, chloramphenicol, ciprofloxacin (CIP), clindamycin, erythromycin (ERY), gentamicin, nalidixic acid and tetracycline. Data regarding antimicrobial use were collected from 250 cases. RESULTS: Of the 250 cases, 165 (65.7%) reported staying home or being hospitalized due to campylobacteriosis. Fifty-four per cent of cases (135 of 249) reported taking antimicrobials to treat campylobacteriosis. In 115 cases (51.1%), fecal culture results were not used for treatment decisions because they were not available before the initiation of antimicrobial treatment and/or they were not available before the cessation of symptoms. Of the 250 cases, 124 (49.6%) had available Campylobacter isolates, of which 66 (53.2%) were resistant to at least one of the antimicrobials tested. No resistance to ampicillin, chloramphenicol or gentamicin was found in these isolates. Six isolates (4.8%) were resistant to CIP. Two isolates (1.6%) were resistant to ERY; however, no isolates were resistant to both CIP and ERY. CONCLUSION: Prudent use practices should be promoted among physicians to reduce the use of antimicrobials for the treatment of gastroenteritis in general and campylobacteriosis in particular, as well as to minimize the future development of resistance to these antimicrobials in Campylobacter species.
AIM: A population-based study was conducted over a two-year period in the Perth District (PD) and Wellington-Dufferin-Guelph (WDG) health units in Ontario to document antimicrobial resistance and antimicrobial use associated with clinical cases of laboratory-confirmed campylobacteriosis. METHODS: Etest (bioMérieux SA, France) was used to determine the minimum inhibitory concentration of amoxicillin/clavulanic acid, ampicillin, chloramphenicol, ciprofloxacin (CIP), clindamycin, erythromycin (ERY), gentamicin, nalidixic acid and tetracycline. Data regarding antimicrobial use were collected from 250 cases. RESULTS: Of the 250 cases, 165 (65.7%) reported staying home or being hospitalized due to campylobacteriosis. Fifty-four per cent of cases (135 of 249) reported taking antimicrobials to treat campylobacteriosis. In 115 cases (51.1%), fecal culture results were not used for treatment decisions because they were not available before the initiation of antimicrobial treatment and/or they were not available before the cessation of symptoms. Of the 250 cases, 124 (49.6%) had available Campylobacter isolates, of which 66 (53.2%) were resistant to at least one of the antimicrobials tested. No resistance to ampicillin, chloramphenicol or gentamicin was found in these isolates. Six isolates (4.8%) were resistant to CIP. Two isolates (1.6%) were resistant to ERY; however, no isolates were resistant to both CIP and ERY. CONCLUSION: Prudent use practices should be promoted among physicians to reduce the use of antimicrobials for the treatment of gastroenteritis in general and campylobacteriosis in particular, as well as to minimize the future development of resistance to these antimicrobials in Campylobacter species.
Authors: Anne Deckert; Alfonso Valdivieso-Garcia; Richard Reid-Smith; Susan Tamblyn; Patrick Seliske; Rebecca Irwin; Cate Dewey; Patrick Boerlin; Scott A McEwen Journal: J Food Prot Date: 2010-07 Impact factor: 2.077
Authors: A E Deckert; R J Reid-Smith; S Tamblyn; L Morrell; P Seliske; F B Jamieson; R Irwin; C E Dewey; P Boerlin; S A McEwen Journal: Epidemiol Infect Date: 2013-03-08 Impact factor: 4.434
Authors: Ousmane Dramé; Daniel Leclair; E Jane Parmley; Anne Deckert; Blaise Ouattara; Danielle Daignault; André Ravel Journal: Foodborne Pathog Dis Date: 2020-03-04 Impact factor: 3.171